Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789477 · ClinicalTrials.gov registry record · Phase 2
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT00789477 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 221 participants.
The verdict
NCT00789477, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and EU.
Interventions
- DRUG Intravitreal Aflibercept Injection
- PROCEDURE Laser Photocoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789477
The ClinicalTrials.gov registry entry for NCT00789477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravitreal Aflibercept Injection is the first listed.
NCT00789477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789477 about?
NCT00789477 is a clinical study titled "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact". This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and EU.
What is the current status of trial NCT00789477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2008-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00789477?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG), Laser Photocoagulation (PROCEDURE).
Who is sponsoring clinical trial NCT00789477?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.